title: Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease.
abstract: Quercetin has been identified as a promising compound with a neuroprotective potential against age-related neurodegenerative diseases such as Alzheimer's disease (AD). Nevertheless, the clinical application of quercetin is hampered by its low oral bioavailability. The aim of this work was to evaluate the capability of nanoencapsulated quercetin in zein nanoparticles (NPQ), that significantly improves the oral absorption and bioavailability of the flavonoid, as potential oral treatment for AD. For this purpose, SAMP8 mice were orally treated for two months with either NPQ (25mg/kg every 48h) or a solution of quercetin (Q; 25mg/kg daily). NPQ displayed a size of 260nm and a payload of about 70μg/mg. For Q, no significant effects were observed in animals. On the contrary, the oral administration of NPQ improved the cognition and memory impairments characteristics of SAMP8 mice. These observations appeared to be related with a decreased expression of the hippocampal astrocyte marker GFAP. Furthermore, significant levels of quercetin were quantified in the brain of mice treated with nanoparticles. These findings highlight the potential of zein nanoparticles to promote the oral absorption of quercetin as well as the therapeutic potential of this flavonoid in AD pathogenesis.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Pamplona, Spain; Immunopathology Keizo-Asami Laboratory, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Lina Clara Gayoso E Ibiapina
authors.initials: LCGEI
authors.lastname: Moreno
authors.affiliation: Department of Pharmacology and Toxicology, University of Navarra, Pamplona, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Puerta
authors.affiliation: Department of Pharmacology and Toxicology, University of Navarra, Pamplona, Spain.
authors.forename: José Eduardo
authors.initials: JE
authors.lastname: Suárez-Santiago
authors.affiliation: Immunopathology Keizo-Asami Laboratory, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Nereide Stela
authors.initials: NS
authors.lastname: Santos-Magalhães
authors.affiliation: Department of Pharmacology and Toxicology, University of Navarra, Pamplona, Spain.
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Ramirez
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, University of Navarra, Pamplona, Spain. Electronic address: jmirache@unav.es.
authors.forename: Juan M
authors.initials: JM
authors.lastname: Irache
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000284:Administration, Oral; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010316:Particle Size; D011794:Quercetin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045442:Rotarod Performance Test; D015028:Zein / Q000737:chemistry; D047392:beta-Cyclodextrins / Q000737:chemistry
chemical_list: D004337:Drug Carriers; D018696:Neuroprotective Agents; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D015028:Zein; D011794:Quercetin
keywords: 2-hydroxypropyl-β-cyclodextrin (PubChem CID: 44134771); Alzheimer’s disease; Nanoparticles; Oral delivery; Quercetin; Quercetin (PubChem CID: 5280343); SAMP8 mice; Zein (PubChem SID: 47208016)